Elicio Therapeutics (ELTX) Liabilities and Shareholders Equity (2020 - 2026)

Elicio Therapeutics (ELTX) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $22.7 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 19.48% year-over-year to $22.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $106.4 million (down 3.74% YoY) and the FY2025 annual result came in at $25.9 million, down 8.22% from the prior year.
• Liabilities and Shareholders Equity slipped to $22.7 million in Q1 2026, from $25.9 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $81.3 million in Q1 2022 to a low of $15.8 million in Q2 2024.
• A 5-year average of $36.2 million and a median of $28.3 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity sank 76.52% — and 2025, when it surged 87.48%.
• Tracing ELTX's Liabilities and Shareholders Equity over 5 years: stood at $22.7 million in 2022, then grew by 19.78% to $27.1 million in 2023, then gained by 3.8% to $28.2 million in 2024, then slipped by 8.22% to $25.9 million in 2025, then slipped by 12.27% to $22.7 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $22.7 million (Q1 2026), $25.9 million (Q4 2025), and $28.3 million (Q3 2025), per Business Quant data.